Loading…

CONMED CorporationCNMDCompetitor analysis, valuation and peers

United States · USD·Health Care›Medical Specialties

Maker of surgical devices and equipment for orthopedic and general surgery, including arthroscopy and powered surgical instruments.

Momentum strong 74
Mkt cap
$1.43B
US dollars, full cap
Free float
100%
of shares outstanding
$/day
$18.7M
20-day average traded
Fwd P/E
10.4×
forward earnings
ROIC−WACC
-7.2 pp
WACC 8.1%
Hurdle
+22 pp
Req g minus delivered
Next earnings
77 days
3 Feb 2027
Close · USD$48.01
1D-0.8%
1W-5.4%
1M+0.9%
3M-6.6%
6M+29.7%
YTD+18.2%
1Y+15.3%
ATR %4.1%
Beta0.83
52w lowhigh12.4% off high

What CONMED does

Maker of surgical devices and equipment for orthopedic and general surgery, including arthroscopy and powered surgical instruments.

Sells equipment such as arthroscopy towers and power consoles to hospitals and surgery centres, then earns again on the single-use blades, scopes and accessories used in every case, so procedure volumes drive results more than equipment sales. Surgeon preference for familiar instruments helps hold the base.

Products and services

  • Arthroscopy/sports medicine devices
  • Powered surgical instruments
  • General surgery/endoscopic devices
  • Advanced surgical energy devices

Customers

  • Orthopedic surgeons
  • General surgeons
  • Hospitals/ASCs

Where it sits in the supply chain

  • Medical devices
  • Surgical devices
  • Orthopedic & general surgery equipment

What could go right

  • Outpatient/ASC surgical volume growth
  • Sports medicine procedure growth

What could go wrong

  • Hospital capex cyclicality
  • Competitive orthopedic device pricing

Moat: narrow (brand, installed base, switching costs). Established surgical brand with installed capital equipment base creating recurring disposables revenue.

Headquarters: Largo, Florida · Founded: 1970 · Employees: 3,900

Named competitors

CONMED at a glance

Size CONMED (CNMD) is a United States Health Care company (Medical Specialties) with a market value of $1.43B, the 1997th largest of 3,085 United States companies the cockpit tracks. Shares closed at $48.01 on 18 Nov 2026.

Performance Over six months the shares gained 29.7%, against -10.2% for the median peer and -2.2% for the United States market (cap-weighted) — 2nd highest of 21 in its peer set.

Growth Revenue grew 1.9% over the last twelve months (peer median +12.1%); the operating margin is 1.6% (peer median 8.2%).

Valuation It trades at 10.4× forward earnings against a peer median of 27.0× (2nd cheapest of 18).

Price implies For today's price to make sense, revenue must grow about 32% a year for seven years (Req g). Recent delivered growth is +10%, so the hurdle is +22 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 7.2 points below its cost of capital (8.1% WACC).

Credit CONMED has 1 bond outstanding ($155M).

Short interest Short interest is 6.2% of the free float (30 Oct 2026).

Next results Next results expected around 3 Feb 2027 (exchange calendar; dates can move).

Relative performance

8010012014021 May 202621 Aug 202618 Nov 2026CNMD 130Peer median 91
Six months, rebased to 100: CONMED against the median of its 20 peers (local-currency closes).

CONMED financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$1.37B$1.37B$1.30B$1.24B$1.03B
Revenue growth—+6%+5%+20%—
Gross profit$615M$725M$695M$643M$528M
EBITDA$76.0M$193M$216M$182M$133M
Net income$73.4M$47.1M$132M$64.5M-$80.6M
Free cash flow$133M$151M$154M$106M$11.6M
Capital expenditure$13.6M$19.8M$13.1M$19.0M$21.8M
Total debt$816M$887M$947M$991M$1.07B

Quarterly statements and history in the cockpit →

CONMED competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%-20%0%+20%PRCT300298300049ELN3005956880166849688198688758ENOV300633VITR688531301087STAA6699BFLYNVCR6882898086CNMD6-month return →1-month return →
Up and to the right = strong over both horizons. CONMED is the large dot.

Fundamentals: revenue growth against valuation

0%+25%+50%+75%20×40×300298300049ELN300595688016688198688758ENOV300633VITR688531301087STAA66996882898086CNMDRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. CONMED is the large dot.

Capital: growth delivered against growth the price implies

0%+10%+20%+30%0%20%300298300049ELN3005956880166849688198688758ENOVVITR301087STAA6699CNMDGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. CONMED is the large dot.

CONMED competitors and peer comparison

Head to head with its named competitors (CNMD vs SYK vs ZBH vs SN..L)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
CONMED CNMD$1.43B+30%+2%2%10.4×31.6%
Stryker SYK$121B-1%+8%25%19.9×10.7%
Zimmer Biomet ZBH$19.6B+21%+7%16%11.7×7.4%
Smith & Nephew SN..L$12.6B+1%+2%17%14.2×11.1%

How CONMED compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

CONMED against its 20 peers (data as of 18 Nov 2026)
MeasureCNMDPeer medianRank in peer set
1-month return+0.9%-1.6%9th highest of 21
6-month return+29.7%-10.2%2nd highest of 21
Distance from 52-week high-12.4%-30.3%2nd highest of 21
Revenue growth (TTM)+1.9%+12.1%5th lowest of 21
Operating margin1.6%8.2%5th lowest of 21
Forward P/E10.4×27.0×2nd cheapest of 18
Growth the price implies (Req g, 7 yrs)31.6%11.2%2nd most demanding of 14
Growth delivered (Del g)+9.8%+16.5%6th lowest of 14
Hurdle (Req g minus delivered)+21.8 pp-6.8 pp3rd most demanding of 14
ROIC minus cost of capital-7.2 pp+0.5 pp5th lowest of 21
EV / EBITDA28.9×12.3×2nd most expensive of 8
Net debt / EBITDA10.1×-1.6×most indebted of 8

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
CONMED CNMDUnited States$1.43B+30%+2%2%10.4×31.6%+9.8%
PROCEPT BioRobotics PRCTUnited States$1.45B-10%+17%-34%n/an/an/a
Sinocare 300298.SZChina$1.45B+4%+7%6%21.5×9.5%+18.3%
Inner Mongolia Furui Medical Science 300049.SZChina$1.45B-31%+11%25%41.9×2.9%+14.6%
El.En ELN.MIItaly$1.46B+11%+3%15%22.0×10.7%+7.7%
Ovctek China 300595.SZChina$1.33B-25%0%28%19.4×8.3%+16.5%
Shanghai MicroPort Endovascular MedTech 688016.SSChina$1.55B-19%+16%44%16.4×2.7%+23.4%
Nihon Kohden 6849.TJapan$1.55B+3%0%7%18.8×-3.5%+3.3%
Beijing Balance Medical Technology 688198.SSChina$1.31B-32%+10%28%41.5×20.7%+27.6%
Suzhou Sepax Technologies 688758.SSChina$1.31B+8%+28%40%46.0×22.8%+23.6%
Enovis ENOVUnited States$1.56B+2%+3%4%7.6×20.0%-6.0%
Sonoscape Medical 300633.SZChina$1.31B-10%+18%4%34.7×n/an/a
Vitrolife VITR.STSweden$1.57B+13%-2%19%27.0×22.2%+22.5%
Wuxi Unicomp Technology 688531.SSChina$1.58B-49%+53%12%35.8×n/an/a
Cofoe Medical Technology 301087.SZChina$1.60B-6%+33%10%25.1×11.2%+7.4%
STAAR Surgical STAAUnited States$1.27B-23%+42%7%46.9×35.1%+7.9%
Angelalign Technology 6699.HKHong Kong$1.62B-8%+84%9%52.5×16.7%+25.8%
Butterfly Network BFLYUnited States$1.63B+38%+39%-36%n/an/an/a
NovoCure NVCRUnited States$1.25B-40%+13%-17%n/an/an/a
Sansure Biotech 688289.SSChina$1.24B-17%-1%1%35.6×n/an/a
NIPRO 8086.TJapan$1.68B-11%+5%5%15.8×n/an/a

CONMED bonds and credit

CONMED has 1 bond outstanding with $155M face value.

Every bond, yield and spread in the cockpit →

Questions

Who are CONMED's main competitors?
Named competitors: Stryker (SYK), Zimmer Biomet (ZBH), Smith & Nephew (SN..L). The cockpit's measured peer set (industry) also includes PROCEPT BioRobotics (PRCT), Sinocare (300298.SZ), Inner Mongolia Furui Medical Science (300049.SZ), El.En (ELN.MI), Ovctek China (300595.SZ), Shanghai MicroPort Endovascular MedTech (688016.SS).
Is CONMED expensive compared with its peers?
On forward p/e it trades at 10.4× against a peer median of 27.0×, 2nd cheapest of 18 in its peer set. For today's price to make sense, revenue must grow about 32% a year for seven years (Req g). Recent delivered growth is +10%, so the hurdle is +22 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has CONMED stock performed?
Over six months to 18 Nov 2026 the shares returned +29.7% against -10.2% for the median peer; over one year +15.3%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.